DisruPep S.L. was born in 2020 as a spanish biotech with technology for the development of peptide-based drugs. DisruPep is a spin-off Technology-Based Company of the Cajal Institute in Madrid within an important laboratory of neuroscience. Cajal Institute take part of the Spanish National Research Council (Spanish: Consejo Superior de Investigaciones Científicas, CSIC) is the largest public institution dedicated to research in Spain and the third largest in Europe.
DisruPep was created with the purpose of developing and exploiting as a licensee a drug candidate as a therapy for post-traumatic stress disorder (PTSD): the QBP1 peptide. As well as development of other drugs and products forming a company of high scientific and business interest.
Working with optimism to improve the lives of people suffering from PTSD, Type 2 Diabetes, Parkinson's and ALS.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Avenida Del Dr. Arce, 37, Madrid,madrid 28002,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://disrupep.com
- Keywords
- Valencia.
- HQ
- Madrid, Madrid
Disrupep Questions
Disrupep's website is https://disrupep.com
Disrupep's LinkedIn profile is https://es.linkedin.com/company/disrupep
Disrupep has
2 employees.
View email and phone details for 2
employees at Disrupep.
Disrupep's industry is
Biotechnology Research
Disrupep's top competitors are
N-Gene,
Escuelablw.com,
Cuver Ibérica S.l,
Enisa. Impulso Financiero A La Pyme,
Enpresa Institutua - Instituto De Economía Aplicada A La Empresa,
Hazquetecompren™,
27metas,
Grillco,
Salud Ikigai,
Biotasmart.
Disrupep's categories are Biotechnology Research
Disrupep's founding year is 2020
